GNBTQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GNBTQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Generex Biotechnology's total inventories for the quarter that ended in Apr. 2021 was $0.23 Mil. Generex Biotechnology's average total inventories from the quarter that ended in Jan. 2021 to the quarter that ended in Apr. 2021 was $0.43 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Generex Biotechnology's Net-Net Working Capital per share for the quarter that ended in Apr. 2021 was $-0.86.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Generex Biotechnology's Days Inventory for the three months ended in Apr. 2021 was 587.59.
Inventory Turnover measures how fast the company turns over its inventory within a year. Generex Biotechnology's Inventory Turnover for the quarter that ended in Apr. 2021 was 0.16.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Generex Biotechnology's Inventory-to-Revenue for the quarter that ended in Apr. 2021 was 20.24.
The historical data trend for Generex Biotechnology's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generex Biotechnology Annual Data | |||||||||||||||||||||
Trend | Jul11 | Jul12 | Jul13 | Jul14 | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | - | 0.01 | 0.01 | 0.36 | 0.74 |
Generex Biotechnology Quarterly Data | ||||||||||||||||||||
Jul16 | Oct16 | Jan17 | Apr17 | Jul17 | Oct17 | Jan18 | Apr18 | Jul18 | Oct18 | Jan19 | Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | |
Total Inventories | Get a 7-Day Free Trial | 0.91 | 0.74 | 0.72 | 0.62 | 0.23 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Generex Biotechnology (OTCPK:GNBTQ) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Generex Biotechnology's Net-Net Working Capital Per Share for the quarter that ended in Apr. 2021 is
Net-Net Working Capital Per Share (Q: Apr. 2021 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (1.675 | + | 0.75 * 0.052 | + | 0.5 * 0.232 | - | 94.081 |
- | 0 | - | 8.176) | / | 116.279 | ||
= | -0.86 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Generex Biotechnology's Days Inventory for the three months ended in Apr. 2021 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Apr. 2021 ) | / | Cost of Goods Sold (Q: Apr. 2021 ) | * | Days in Period |
= | 0.425 | / | 0.066 | * | 365 / 4 | |
= | 587.59 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Generex Biotechnology's Inventory Turnover for the quarter that ended in Apr. 2021 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Apr. 2021 ) | / | Average Total Inventories (Q: Apr. 2021 ) |
= | 0.066 | / | 0.425 | |
= | 0.16 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Generex Biotechnology's Inventory to Revenue for the quarter that ended in Apr. 2021 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Apr. 2021 ) | / | Revenue (Q: Apr. 2021 ) |
= | 0.425 | / | 0.021 | |
= | 20.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Generex Biotechnology's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Prioletti Mark Joseph Se | director | 1121 PALMER COURT CRYSTAL LAKE IL 60014 |
Salvo Lawrence Anthony Sr | director | 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139 |
Harold Gray Haines | other: Consultant | 11511 SW 127TH ST MIAMI FL 33176 |
Mark Fletcher | officer: EVP General Counsel &Secretary | 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3 |
Brian Mcgee | director | 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000 |
Anderson James H Jr. | director | 33 HARBOUR SQUARE TORONTO A6 M5J2G2 |
Mark Corrao | officer: CFO & Treasurer | 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825 |
Purcell Richard David Jr. | director, officer: SVP of Research & Drug Develop | 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704 |
Gary Herbert Lyman | director | 10102 USA TODAY WAY MIRAMAR FL 33025 |
Kevin Centofanti | director | 10102 USA TODAY WAY MIRAMAR FL 33025 |
Andrew Ro | director, officer: SVP & Chief Investment Officer | 10102 USA TODAY WAY MIRAMAR FL 33025 |
David Brusegard | officer: Chief Operating Officer | 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3 |
Stephen Fellows | officer: Chief Financial Officer | 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2 |
Hofe Eric Von | director, officer: President of Subsidiary | 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3 |
John P Barratt | director | 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1 |
From GuruFocus
By Marketwired Marketwired • 09-09-2020
By Marketwired Marketwired • 11-18-2020
By Marketwired Marketwired • 04-27-2021
By Marketwired Marketwired • 10-13-2020
By Marketwired Marketwired • 02-24-2021
By Marketwired Marketwired • 09-18-2020
By Marketwired Marketwired • 09-25-2020
By Marketwired Marketwired • 05-03-2021
By Marketwired Marketwired • 11-12-2020
By Marketwired Marketwired • 08-27-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.